Listen & Watch

  1. Nobody Puts Plasmid In A Corner: Essential Considerations For mRNA Production 9/8/2026

    This Advancing Live panel discussion featuring CPI's Philip Probert, Sanofi's Nicolas Chaudet, Tune Therapeutics' Tyler Goodwin, and USP's Ben Clarke digs into the current analytical and manufacturing paradigms for plasmid DNA, touching on the advancements and remaining questions surrounding our understanding of plasmid quality and its impact on mRNA quality.

  2. The mRNA Therapeutics Regulatory Paradigm: A Closer Look 7/9/2026

    FDA leadership changes and new advanced therapy guidances are reshaping the mRNA landscape. Explore the latest regulatory developments and what they mean for developers.

  3. Evolutions in mRNA Drug Product Analytical Development 5/19/2026

    How well do we know our mRNA-LNP drug products today? In this discussion, Advancing RNA panelists unpack what we continue to learn about the analytical methods we have at our disposal today, while identifying which attributes we should be paying closer attention to today.

  4. Closing The Adoption Gap For Advanced Single-Use Materials 4/28/2026

    This panel discussion examined how regulatory lag, evolving biocompatibility standards, and the complexity of converting legacy systems slow the uptake of innovative single-use materials and technologies in biomanufacturing. This conversation featured BioPlan Associates’ director of research, Katrina Cordovado, as well as Joshua Nelson, Ph.D., a senior material qualification specialist at Takeda, and Paul Priebe, a consultant and single-use bioprocessing technology expert.

  5. Advancements in gRNA Manufacturing & Quality 3/26/2026

    Guide RNA is a critical component of a gene editing therapy. However, the current manufacturing (solid phase synthesis) and analytical paradigms remain insufficient for such large, complex molecules.

  6. Chemoenzymatic Ligation: A New Frontier In siRNA Manufacturing 2/26/2026

    The current oligo manufacturing paradigm relies on solid-phase synthesis, a process heavily reliant on organic solvents/raw materials. However, siRNA manufacturers—both biotechs and CDMOs—are in the process of starting a slow but important manufacturing transition away from solid phase synthesis toward enzymatic production, starting with enzymatic ligation for siRNA products.

  7. Advancements In Targeted LNP Therapy 1/21/2026

    We’re still striving to deliver mRNA-LNPs to cells/tissue types that go beyond the liver. Outside of exploring different lipid combinations to expand mRNA-LNPs’ deliverability to new tissues, this discussion featuring Dominik Witzigmann, John Zuris, and Sujit Jain investigated the industry’s push toward active delivery to improve targeting, as well as other advancements being made to improve LNP development, quality, & deliverability.

  8. Unlocking The Future: Innovations In The mRNA And Oligo Supply Chains 11/12/2025

    In this forward-looking Advancing RNA event we explore the current and next generation of raw materials shaping the mRNA and oligo therapeutics landscapes. We've brought together industry leaders to discuss advancements in raw materials, including novel enzymes, optimized capping reagents, and other essential materials. We look at how the current generations of materials are informing the quality of our mRNA and oligo products, while also exploring how each sector of the RNA industry is working with next-gen raw materials to reduce COGS and improve manufacturing efficiency, product quality, and supply chain resilience. 

  9. Process Development Considerations For Next-Gen RNA Therapeutics 9/24/2025

    As additional mRNA therapeutics makers progress toward and into the clinic, we've begun to gather more knowledge about what makes our mRNA products "tick," and how our processes impact the overall quality of our products.

  10. RNA Delivery Reimagined: Innovative Nonviral Strategies Beyond LNPs 7/9/2025

    In this Advancing RNA Live, our editorial and community director Anna Rose Welch was joined by several leaders in the world of nucleic acid nonviral delivery beyond the “tried-and-true” LNP.